Fwd: TS Balganesh, head of Open Source Drug Discovery, an initiative of the Indian Government-supported Council for Scientific and Industrial Research, expressed sadness over the closure of AZ R&D in Bangalore and Piramal’s exit from the new drug discovery business.

[jaleel uc]

India’s Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services. This is the second new drug discovery unit being shut down in India this year, following AstraZeneca’s (AZ) closure of its R&D centre for neglected diseases in Bangalore in January.

http://www.rsc.org/chemistryworld/2014/09/piramal-exits-drug-discovery-india

--
 JALEEL

--
 JALEEL